Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
39,510,250
-
Share change
-
+6,411,336
-
Total reported value
-
$350,604,388
-
Price per share
-
$8.88
-
Number of holders
-
72
-
Value change
-
+$56,686,370
-
Number of buys
-
49
-
Number of sells
-
13
Institutional Holders of THESEUS PHARMACEUTICALS INC - COM (THRX) as of Q1 2023
As of 31 Mar 2023,
THESEUS PHARMACEUTICALS INC - COM (THRX) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,510,250 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Foresite Capital Management V, LLC, Frazier Life Sciences Management, L.P., Fairmount Funds Management LLC, Paradigm Biocapital Advisors LP, PRICE T ROWE ASSOCIATES INC /MD/, FMR LLC, BlackRock Inc., VR Adviser, LLC, and Lynx1 Capital Management LP.
This page lists
72
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.